MA41957A - Conjugués d'une fraction d'il-7 et d'un polymère - Google Patents

Conjugués d'une fraction d'il-7 et d'un polymère

Info

Publication number
MA41957A
MA41957A MA041957A MA41957A MA41957A MA 41957 A MA41957 A MA 41957A MA 041957 A MA041957 A MA 041957A MA 41957 A MA41957 A MA 41957A MA 41957 A MA41957 A MA 41957A
Authority
MA
Morocco
Prior art keywords
conjugates
fraction
polymer
Prior art date
Application number
MA041957A
Other languages
English (en)
Inventor
Deborah H Charych
Peter Benecict Kirk
Ping Zhang
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA41957A publication Critical patent/MA41957A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2046IL-7
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041957A 2015-03-11 2016-03-11 Conjugués d'une fraction d'il-7 et d'un polymère MA41957A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562131634P 2015-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
MA41957A true MA41957A (fr) 2018-02-28

Family

ID=56878892

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041957A MA41957A (fr) 2015-03-11 2016-03-11 Conjugués d'une fraction d'il-7 et d'un polymère

Country Status (11)

Country Link
US (1) US20190290733A1 (fr)
EP (1) EP3285799A4 (fr)
JP (3) JP2018510863A (fr)
KR (1) KR20170125839A (fr)
CN (1) CN107405384A (fr)
AU (1) AU2016228555B2 (fr)
CA (1) CA2978330C (fr)
IL (1) IL254389B2 (fr)
MA (1) MA41957A (fr)
MX (1) MX2017011562A (fr)
WO (1) WO2016145388A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
BRPI0719446A2 (pt) 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
CA2908198A1 (fr) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3302547A1 (fr) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
WO2017035232A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2020121071A1 (fr) * 2018-12-12 2020-06-18 Levim Biotech Llp Procédé d'acylation pour la préparation de peptide n-substitué
WO2022020637A1 (fr) * 2020-07-22 2022-01-27 Nektar Therapeutics Composition d'agonistes du récepteur il-7, et méthodes et utilisations associées
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2002085300A2 (fr) * 2001-04-23 2002-10-31 The Regents Of The University Of California Utilisation de l'interleukine 7 pour moduler des processus physiologiques des fibroblastes pulmonaires de mammiferes
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
EP1391513A1 (fr) * 2002-08-08 2004-02-25 Cytheris Substance médicamenteuse IL-7, composition comprenant IL-7, procédé de sa préparation et ses utilisations
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP1819728B1 (fr) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Variants de l'il-7 a immunogenicite reduite
EP2242505A4 (fr) * 2008-01-08 2012-03-07 Biogenerix Ag Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
KR102472497B1 (ko) * 2010-11-12 2022-11-29 넥타르 테라퓨틱스 Il-2 부분 및 중합체의 접합체
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (fr) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugués d'une fraction il-11 et d'un polymère
WO2013074489A1 (fr) * 2011-11-14 2013-05-23 Emory University Conjugués de gm-csf et d'il-7, compositions en contenant et méthodes associées

Also Published As

Publication number Publication date
CN107405384A (zh) 2017-11-28
IL254389B (en) 2022-11-01
JP2021091708A (ja) 2021-06-17
WO2016145388A1 (fr) 2016-09-15
EP3285799A1 (fr) 2018-02-28
AU2016228555B2 (en) 2021-12-23
JP2018510863A (ja) 2018-04-19
KR20170125839A (ko) 2017-11-15
IL254389A0 (en) 2017-11-30
IL254389B2 (en) 2023-03-01
MX2017011562A (es) 2018-05-11
AU2016228555A1 (en) 2017-08-31
CA2978330A1 (fr) 2016-09-15
EP3285799A4 (fr) 2018-08-08
US20190290733A1 (en) 2019-09-26
CA2978330C (fr) 2024-01-09
JP2022163194A (ja) 2022-10-25

Similar Documents

Publication Publication Date Title
MA41957A (fr) Conjugués d'une fraction d'il-7 et d'un polymère
MA49715A (fr) Oligomères et conjugués d'oligomères
DK3592393T3 (da) Frigørbare konjugater
BR112017008404A2 (pt) seringa com auto-orientação e interface se seringa
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
FR3016945B1 (fr) Plaque d'amortissement
FR3019522B1 (fr) Ensemble sustentateur amovible d'un giravion et giravion
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
BR112016003413A2 (pt) prancha ergometrica de uma esteira ergometrica e esteira ergometrica
FR3033706B3 (fr) Simulateur d'escalier
FI20146023A (fi) Hammas- ja kielituki
MA49905A (fr) Polyesteramines et polyesterquats
FR3033707B3 (fr) Simulateur d'escalier
MA43873A (fr) Dspositif d'injection
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater
DK3018383T3 (da) Afslutning af styrkeelementer i dybhavskabler
MA42954A (fr) Potentialisateurs cftr deutérés
DE202014105547U8 (de) Steckverbinder und Steckverbindung
FI20160028A (fi) Tolpan perustus
DK3176187T4 (da) Hærdbar polymersammensætning
DK3099314T3 (da) Tolerogene sammensætninger og anvendelser deraf
MA45326A (fr) Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
UA37080S (uk) Спортивний майданчик
UA36873S (uk) Спортивний майданчик